- Home
- STEC vs KALA Comparison
STEC vs KALA Comparison
Compare STEC & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- KALA
- Stock Information
- Founded
- STEC 2006
- KALA 2009
- Country
- STEC Hong Kong
- KALA United States
- Employees
- STEC N/A
- KALA N/A
- Industry
- STEC
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- KALA Health Care
- Exchange
- STEC NYSE
- KALA Nasdaq
- Market Cap
- STEC 29.7M
- KALA 26.2M
- IPO Year
- STEC 2021
- KALA 2017
- Fundamental
- Price
- STEC $0.73
- KALA $5.48
- Analyst Decision
- STEC
- KALA Strong Buy
- Analyst Count
- STEC 0
- KALA 3
- Target Price
- STEC N/A
- KALA $14.00
- AVG Volume (30 Days)
- STEC 12.9K
- KALA 125.5K
- Earning Date
- STEC 07-22-2025
- KALA 08-05-2025
- Dividend Yield
- STEC N/A
- KALA N/A
- EPS Growth
- STEC N/A
- KALA N/A
- EPS
- STEC N/A
- KALA N/A
- Revenue
- STEC $10,672,000.00
- KALA N/A
- Revenue This Year
- STEC $9,392.20
- KALA N/A
- Revenue Next Year
- STEC N/A
- KALA N/A
- P/E Ratio
- STEC N/A
- KALA N/A
- Revenue Growth
- STEC N/A
- KALA N/A
- 52 Week Low
- STEC $0.20
- KALA $2.92
- 52 Week High
- STEC $3.25
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- STEC 32.63
- KALA 55.78
- Support Level
- STEC $0.81
- KALA $4.36
- Resistance Level
- STEC $0.88
- KALA $7.00
- Average True Range (ATR)
- STEC 0.07
- KALA 0.75
- MACD
- STEC -0.01
- KALA 0.07
- Stochastic Oscillator
- STEC 35.80
- KALA 49.17
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.